ISOFOL 12.84 SEK (-0.16) 03 Dec 2021 17:29 OCTOBER 21, 2021 TRADING IN ISOFOL'S SHARES BEGINS TODAY ON NASDAQ STOCKHOLM Click here for more information >> Media Isofol Medical AB (publ) does not reach 300 PFS incidents in the AGENT study with current censorship rules based on FDA decisions December 3, 2021 GOTHENBURG, Sweden, December 3, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) announced today that the US Food and Drug Administration FDA… Isofol Medical AB (publ) is granted Fast Track Designation by the FDA for arfolitixorin for the treatment of advanced colorectal cancer November 23, 2021 GOTHENBURG, Sweden, 23 November 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) announced today that the US Medicines Agency (FDA)… Isofol has appointed the Nomination Committee for the 2022 Annual General Meeting November 19, 2021 GOTHENBURG, Sweden, 19 November 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (“Isofol” or “the Company”), announced today that the Nomination Committee's Upcoming Event December 16, 2021 - December 16, 2021 DNB Nordic Healthcare Conference 2021 Isofol will participate in the event with a presentation of Isofol and in a question and answer session. Investors have the opportunity to meet the company in individual meetings or smaller group meetings. January 20, 2022 - January 20, 2022 Redeye Fight cancer seminar 2022 February 24, 2022 - February 24, 2022 Year-end report 2021 About Isofol Isofol Medical AB (publ) är ett biotechbolag verksamt inom onkologi som utvecklar cancerläkemedlet arfolitixorin. Arfolitixorin är en ny läkemedelskandidat som främst är avsett för behandling av kolorektalcancer (CRC), en av de vanligaste formerna av cancer. Isofol utvecklar även arfolitixorin för så kallad räddningsbehandling efter högdosbehandling med cellgiftet metotrexat vid osteosarkom (bencancer). Kontakt Isofol Medical AB (publ) Biotech Center, Arvid Wallgrens Backe 20 413 46 Göteborg Sverige Telefon: +46 (0)31 7972280 E-post: info@isofolmedical.com Nyhetsbrev och integritetspolicy Sign up here to receive news, press releases & information and consent to Isofol's processing of your personal data in accordance with the company's privacy policy. Isofol's privacy policy (general) Isofol's privacy policy (clinical trials) © 2018 Isofol Medical AB (publ) Biotech Cente, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden Isofol´s Glossary Isofol's website uses cookies to improve and customize your visit. By continuing you accept this.Accept Read More